A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

General Inclusion Criteria:

≥ 18 years of age
Adequate organ function
Life expectancy ≥ 3 months
Women of childbearing potential must have a negative serum pregnancy test
Advanced/metastatic solid tumor (Phase 1b)
Availability of tumor tissue at screening
ECOG performance status of 0 to 1
Measurable disease (RECIST v1.1) (Phase 2)
Advanced, recurrent, or metastatic gynecological solid tumor (Phase 2)
Willing and able to fast, and to eat a high-fat breakfast (Food Effect)

General Exclusion Criteria:

Prior treatment with lucitanib
Active second malignancy
Active central nervous system brain metastases
Pre-existing duodenal stent or any gastrointestinal disorder
Known history of HIV or AIDs; positive result of hepatitis B or C viruses
Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of myocarditis
Active, known or suspected autoimmune disease (eg, autoimmune hepatitis)
Condition requiring systemic treatment with corticosteroids or other immune suppressive medications
Unstable or uncontrolled hypertension (BP ≥ 140/90 mmHg)
Prior treatment with a VEGFR-tyrosine kinase inhibitor (Phase 2)